卡博替尼治疗铂类化疗后进展的复发或转移性宫颈癌的II期研究(CABOCOL)
这项开放标签II期研究纳入57例既往接受铂类化疗的复发宫颈癌患者,54例接受卡博替尼60mg每日口服。3个月疾病控制率为46.3%,瘘/穿孔发生率为9.3%,中位无进展生存期2.8个月,≥3级治疗相关不良事件发生率为51.9%。结论认为卡博替尼疗效与其他抗血管生成单药相当,但获益有限且毒性不支持进一步单药开发。
要点
- 卡博替尼60mg每日口服的3个月疾病控制率为46.3%。
- 瘘/穿孔发生率为9.3%,≥3级治疗相关不良事件发生率为51.9%。
- 中位无进展生存期2.8个月,客观缓解率9.3%。
核心结论
- 卡博替尼在复发宫颈癌中显示出与其他抗血管生成单药相当的疗效,但获益有限且毒性不支持进一步单药开发。
研究设计与样本
- 开放标签II期研究(NCT04205799),纳入57例既往接受铂类化疗的复发宫颈癌患者,54例接受卡博替尼60mg每日口服直至进展或任何原因停药。
主要发现
- 3个月疾病控制率为46.3%(95%CI,32.8-60.3)。
- 瘘/穿孔发生在5例(9.3%)患者中。
- 客观缓解率为9.3%,中位缓解持续时间为2.5个月。
- 中位无进展生存期为2.8个月(95%CI,2.5-4.6)。
- ≥3级治疗相关不良事件发生率为51.9%,最常见为乏力(15%)、高血压(9%)和黏膜炎(6%)。
关键数值与推荐
- 主要终点为联合主要终点:疗效(3个月疾病控制率)和安全性(≥2级胃肠穿孔、胃肠-阴道和/或泌尿生殖瘘事件比例),采用Bryant-and-Day设计。
临床怎么用
- 卡博替尼单药在复发宫颈癌中获益有限且毒性明显,不支持进一步单药开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The antiangiogenic pathway is an effective target for recurrent uterine cervical carcinoma (rCC). This study evaluated the safety and efficacy of cabozantinib monotherapy for rCC. PATIENTS & METHODS: This open-label phase II study (NCT04205799) enrolled patients with rCC who previously received platinum-based chemotherapy. Patients received oral cabozantinib (60 mg daily) until progression or discontinuation from any cause. The main objective was based on joint primary endpoint of efficacy (3-month disease control rate, DCR3) and safety (proportion of patients with grade ≥ 2 (CTCAE v5.0) gastro-intestinal (GI) perforation, GI-vaginal and/or genito-urinary (GU) fistula events) according to a Bryant-and-Day design. Key secondary endpoints were progression-free survival (PFS), duration of response (DOR) and safety. RESULTS: Among 57 patients enrolled, 54 received cabozantinib: median age was 55.5 years, 18 patients (33.3%) had received more than two prior lines of treatment; 28 patients (51.9%) had been previously treated with bevacizumab. Median duration of follow-up was 8.9 months. DCR3 was 46.3% [95% CI, 32.8-60.3]. Fistula/perforation occurred in 5 (9.3%) patients. Objective response rate was 9.3%, with a median DOR of 2.5 months. Median PFS was 2.8 months (95% CI, 2.5-4.6). Grade ≥ 3 treatment-related adverse events occurred in 51.9% of patients, most commonly asthenia (15%), hypertension (9%) and mucositis (6%). Dose reductions and treatment interruptions were reported in 26 (48%) and 24 (44%) patients, respectively. CONCLUSIONS: Cabozantinib demonstrates efficacy comparable to other anti-angiogenic monotherapy in rCC; however, modest benefit and toxicity do not support further monotherapy development.
引用
- Coquan E, Vion R, Colomba-Blamemble E, et al. Phase II study of cabozantinib in recurrent or metastatic cervical cancer after progression on platinum-based chemotherapy (CABOCOL). Gynecol Oncol. 2026. PMID: 42914775. doi:10.1016/j.ygyno.2026.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。